These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 27363726)

  • 21. Epigenetic mechanisms in the pathogenesis of Lynch syndrome.
    Peltomäki P
    Clin Genet; 2014 May; 85(5):403-12. PubMed ID: 24443998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening for Lynch syndrome using risk assessment criteria in patients with ovarian cancer.
    Takeda T; Tsuji K; Banno K; Yanokura M; Kobayashi Y; Tominaga E; Aoki D
    J Gynecol Oncol; 2018 May; 29(3):e29. PubMed ID: 29400022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
    Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
    J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lynch syndrome, molecular mechanisms and variant classification.
    Abildgaard AB; Nielsen SV; Bernstein I; Stein A; Lindorff-Larsen K; Hartmann-Petersen R
    Br J Cancer; 2023 Mar; 128(5):726-734. PubMed ID: 36434153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular Background of Colorectal Tumors From Patients With Lynch Syndrome Associated With Germline Variants in PMS2.
    Ten Broeke SW; van Bavel TC; Jansen AML; Gómez-García E; Hes FJ; van Hest LP; Letteboer TGW; Olderode-Berends MJW; Ruano D; Spruijt L; Suerink M; Tops CM; van Eijk R; Morreau H; van Wezel T; Nielsen M
    Gastroenterology; 2018 Sep; 155(3):844-851. PubMed ID: 29758216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive functional assay-based classification of PMS2 variants in Lynch syndrome.
    Rayner E; Tiersma Y; Fortuno C; van Hees-Stuivenberg S; Drost M; Thompson B; Spurdle AB; de Wind N
    Hum Mutat; 2022 Sep; 43(9):1249-1258. PubMed ID: 35451539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of MLH1 and MSH2 mutations in Lynch syndrome.
    Balmaña J; Stockwell DH; Steyerberg EW; Stoffel EM; Deffenbaugh AM; Reid JE; Ward B; Scholl T; Hendrickson B; Tazelaar J; Burbidge LA; Syngal S
    JAMA; 2006 Sep; 296(12):1469-78. PubMed ID: 17003395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and Validation of the PREMM
    Kastrinos F; Uno H; Ukaegbu C; Alvero C; McFarland A; Yurgelun MB; Kulke MH; Schrag D; Meyerhardt JA; Fuchs CS; Mayer RJ; Ng K; Steyerberg EW; Syngal S
    J Clin Oncol; 2017 Jul; 35(19):2165-2172. PubMed ID: 28489507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mismatch repair deficiency testing in clinical practice.
    Buza N; Ziai J; Hui P
    Expert Rev Mol Diagn; 2016; 16(5):591-604. PubMed ID: 26895074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.
    Bancroft EK; Page EC; Brook MN; Thomas S; Taylor N; Pope J; McHugh J; Jones AB; Karlsson Q; Merson S; Ong KR; Hoffman J; Huber C; Maehle L; Grindedal EM; Stormorken A; Evans DG; Rothwell J; Lalloo F; Brady AF; Bartlett M; Snape K; Hanson H; James P; McKinley J; Mascarenhas L; Syngal S; Ukaegbu C; Side L; Thomas T; Barwell J; Teixeira MR; Izatt L; Suri M; Macrae FA; Poplawski N; Chen-Shtoyerman R; Ahmed M; Musgrave H; Nicolai N; Greenhalgh L; Brewer C; Pachter N; Spigelman AD; Azzabi A; Helfand BT; Halliday D; Buys S; Ramon Y Cajal T; Donaldson A; Cooney KA; Harris M; McGrath J; Davidson R; Taylor A; Cooke P; Myhill K; Hogben M; Aaronson NK; Ardern-Jones A; Bangma CH; Castro E; Dearnaley D; Dias A; Dudderidge T; Eccles DM; Green K; Eyfjord J; Falconer A; Foster CS; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Lilja H; Lindeman GJ; Lubinski J; Axcrona K; Mikropoulos C; Mitra AV; Moynihan C; Ni Raghallaigh H; Rennert G; Collier R; ; Offman J; Kote-Jarai Z; Eeles RA
    Lancet Oncol; 2021 Nov; 22(11):1618-1631. PubMed ID: 34678156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients.
    Hampel H; Frankel W; Panescu J; Lockman J; Sotamaa K; Fix D; Comeras I; La Jeunesse J; Nakagawa H; Westman JA; Prior TW; Clendenning M; Penzone P; Lombardi J; Dunn P; Cohn DE; Copeland L; Eaton L; Fowler J; Lewandowski G; Vaccarello L; Bell J; Reid G; de la Chapelle A
    Cancer Res; 2006 Aug; 66(15):7810-7. PubMed ID: 16885385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cascade screening in HBOC and Lynch syndrome: guidelines and procedures in a UK centre.
    Evans DG; Green K; Burghel GJ; Forde C; Lalloo F; Schlecht H; Woodward ER
    Fam Cancer; 2024 Jun; 23(2):187-195. PubMed ID: 38478259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Penetrance estimates for
    Evans DG; Woodward E; Harkness EF; Howell A; Plaskocinska I; Maher ER; Tischkowitz MD; Lalloo F
    J Med Genet; 2018 Jul; 55(7):442-448. PubMed ID: 29483236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic mutation risk calculation in Lynch syndrome inheritance: Evaluating the utility of the PREMM
    Aissaoui S; Cartellier C; Seytier T; Giraud S; Calender A
    Bull Cancer; 2017 Mar; 104(3):288-294. PubMed ID: 28038733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mismatch repair gene pathogenic germline variants in a population-based cohort of breast cancer.
    Nguyen-Dumont T; Steen JA; Winship I; Park DJ; Pope BJ; Hammet F; Mahmoodi M; Tsimiklis H; Theys D; Clendenning M; Giles GG; Hopper JL; Southey MC
    Fam Cancer; 2020 Jul; 19(3):197-202. PubMed ID: 32060697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
    Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
    Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding the Pathogenicity of Noncoding Mismatch Repair Gene Promoter Variants in Lynch Syndrome.
    Liu Q; Thompson BA; Ward RL; Hesson LB; Sloane MA
    Hum Mutat; 2016 May; 37(5):417-26. PubMed ID: 26888055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumour characteristics provide evidence for germline mismatch repair missense variant pathogenicity.
    Li S; Qian D; Thompson BA; Gutierrez S; Wu S; Pesaran T; LaDuca H; Lu HM; Chao EC; Black MH
    J Med Genet; 2020 Jan; 57(1):62-69. PubMed ID: 31391288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Consideration of hereditary nonpolyposis colorectal cancer in BRCA mutation-negative familial ovarian cancers.
    South SA; Vance H; Farrell C; DiCioccio RA; Fahey C; Piver MS; Rodabaugh KJ
    Cancer; 2009 Jan; 115(2):324-33. PubMed ID: 19117025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accurate classification of MLH1/MSH2 missense variants with multivariate analysis of protein polymorphisms-mismatch repair (MAPP-MMR).
    Chao EC; Velasquez JL; Witherspoon MS; Rozek LS; Peel D; Ng P; Gruber SB; Watson P; Rennert G; Anton-Culver H; Lynch H; Lipkin SM
    Hum Mutat; 2008 Jun; 29(6):852-60. PubMed ID: 18383312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.